机构：[1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China神经科系统神经内科首都医科大学宣武医院[2]Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA
Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
基金：
National Natural Science Foundation of China [82071468, 82271507]
第一作者机构：[1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China[*1]Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing 100053, China
推荐引用方式(GB/T 7714)：
Yang Nan,Lee Hangil,Wu Chuanjie.Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase[J].BRAIN CIRCULATION.2023,9(2):61-63.doi:10.4103/bc.bc_70_22.
APA：
Yang, Nan,Lee, Hangil&Wu, Chuanjie.(2023).Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase.BRAIN CIRCULATION,9,(2)
MLA：
Yang, Nan,et al."Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase".BRAIN CIRCULATION 9..2(2023):61-63
